Monopar Therapeutics Inc.

MNPR · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$3,438-$2,454-$2,625-$10,926
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$279
Change in WC$248$97-$4,393$4,096
Other Non-Cash$1,099$1,280$1,355$4,552
Operating Cash Flow-$2,091-$1,077-$5,663-$1,998
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$5,726-$1,213-$1,926-$14,338
Inv. Sales/Matur.$3,600$2,400$1,600$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$2,126$1,187-$326-$14,338
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$127,773$5$15$56,204
Stock Repurch.-$35,000$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$382-$322-$131-$67
Financing Cash Flow$92,392-$317-$116$56,137
Forex Effect$0-$3-$0-$4
Net Chg. in Cash$88,175-$209-$6,105$39,796
Supplemental Information
Beg. Cash$39,502$39,711$45,816$6,020
End Cash$127,677$39,502$39,711$45,816
Free Cash Flow-$2,091-$1,077-$5,663-$1,998